Low-dose radioimmuno-therapy of cancer

Four decades of genomic, cellular, animal and human data have shown that low-dose ionizing radiation stimulates positive genomic and cellular responses associated with effective cancer prevention and therapy and increased life span of mammals and humans. 1—8 Nevertheless, this data is questioned bec...

Full description

Saved in:
Bibliographic Details
Published in:Human & experimental toxicology 2008-02, Vol.27 (2), p.169-175
Main Authors: Pollycove, Myron, Feinendegen, Ludwig E
Format: Article
Language:English
Subjects:
Adaptation, Physiological - radiation effects
Animals
Cancer
Controlled Clinical Trials as Topic
Disease Models, Animal
Disease prevention
DNA - radiation effects
DNA Damage
Dose-Response Relationship, Radiation
Humans
Immune System - radiation effects
Immunotherapy
Medical research
Mice
Neoplasms - mortality
Neoplasms - radiotherapy
Radiation therapy
Radioimmunotherapy - methods
Rats
Survival Rate
Toxicology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Four decades of genomic, cellular, animal and human data have shown that low-dose ionizing radiation stimulates positive genomic and cellular responses associated with effective cancer prevention and therapy and increased life span of mammals and humans. 1—8 Nevertheless, this data is questioned because it seems to contradict the well demonstrated linear relation between ionizing radiation dose and damage to DNA without providing a clear mechanistic explanation of how low-dose radiation could produce such beneficial effects. This apparent contradiction is dispelled by current radiobiology that now includes DNA damage both from ionizing radiation and from endogenous metabolic free radicals, and coupled with the biological response to low-dose radiation. Acceptance of current radiobiology would invalidate long established recommendations and regulations of worldwide radiation safety organizations and so destroy the basis of the very expensive existing system of regulation and remediation. More importantly, current radiobiology would facilitate urgently needed clinical trials of low dose radiation (LDR) cancer therapy.
ISSN:0960-3271
1477-0903
DOI:10.1177/0960327107083411